q 2006 by Taylor & Francis Group, LLC - Developers

More documents

Recommendations

Info

q 2006 by Taylor & Francis Group, LLC
q 2006 by Taylor & Francis Group, LLC Dedication To the loving memory of my dad, Mustafa Amiji, and to my mom, Shirin Amiji
Page 1: q 2006 by Taylor & Francis Group, L
Page 7 and 8: Foreword We are at the threshold of
Page 9 and 10: Preface With parallel breakthroughs
Page 11: Editor Dr. Mansoor M. Amiji receive
Page 14 and 15: Robert B. Campbell Department of Ph
Page 16 and 17: Bruce R. Line Department of Radiolo
Page 18 and 19: Vladimir P. Torchilin Department of
Page 20 and 21: Chapter 10 Poly(L-Glutamic Acid): E
Page 22 and 23: Chapter 32 RGD-Modified Liposomes f
Page 24 and 25: 4 Nanotechnology for Cancer Therapy
Page 26 and 27: 6 Nanotechnology for Cancer Therapy
Page 28 and 29: 8 infrastructure to characterize na
Page 30 and 31: 10 Nanotechnology for Cancer Therap
Page 32 and 33: 12 correlated to its diameter. Ther
Page 34 and 35: 14 multidrug-resistance-related pro
Page 36 and 37: 16 optical absorption properties ca
Page 38 and 39: 18 Nanotechnology for Cancer Therap
Page 40 and 41: 20 Targeting Imaging appear to have
Page 42 and 43: 22 3.2.1 COMPOSITION AND BIOCOMPATI
Page 44 and 45: 24 contrast media for detection by
Page 46 and 47: 26 Oppositely, one could envisage h
Page 48 and 49: 28 Many of the differences between
Page 50 and 51: 30 Folate has been used to target d
Page 52 and 53: 32 antigens/agents to stimulate an
Page 54 and 55:
34 identify optimal methods for aer
Page 56 and 57:
36 Nanotechnology for Cancer Therap
Page 58 and 59:
Page 60 and 61:
Page 62 and 63:
Page 64 and 65:
44 4.1 INTRODUCTION The recent deve
Page 66 and 67:
46 (Gly-Phe-Leu-Gly) was developed.
Page 68 and 69:
48 charged generation 5 PAMAM dendr
Page 70 and 71:
50 Using a mannosylated cholesterol
Page 72 and 73:
52 without any changes in the funct
Page 74 and 75:
54 4.4.2.4 Folate Receptor-Mediated
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
60 Targeting species Therapeutic 5.
Page 82 and 83:
62 QD+NLS 70kD Dextran Merge QD+MLS
Page 84 and 85:
64 (a) (b) Peptide Peptide Peptide
Page 86 and 87:
66 (e.g., glycans, lipids, oligonuc
Page 88 and 89:
68 layer-by-layer absorption of pol
Page 90 and 91:
70 5.3 CHALLENGES IN INTEGRATING MU
Page 92 and 93:
Page 94 and 95:
Page 97 and 98:
6 CONTENTS Neutron Capture Therapy
Page 99 and 100:
Neutron Capture Therapy of Cancer 7
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123:
Page 126 and 127:
106 7.5.1 Applicability of Standard
Page 128 and 129:
108 consensus as to what measuremen
Page 130 and 131:
110 a nanomaterial. AFM uses a nano
Page 132 and 133:
112 In addition to size, the shape
Page 134 and 135:
114 presence of all these entities
Page 136 and 137:
116 concentration-dependent changes
Page 138 and 139:
118 limits cellular uptake, resulti
Page 140 and 141:
120 Nanotechnology for Cancer Thera
Page 142 and 143:
Page 144 and 145:
124 been shown to cause liver injur
Page 146 and 147:
Page 148 and 149:
128 7.5.2 IMMUNOGENICITY This issue
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 159 and 160:
8 CONTENTS Nanotechnology: Regulato
Page 161 and 162:
TABLE 8.1 Nanomedicines: Drugs/Devi
Page 163 and 164:
Regulatory Perspective in Nanotechn
Page 165 and 166:
Page 167 and 168:
Page 169 and 170:
Page 171 and 172:
Page 173 and 174:
Page 175 and 176:
Page 177 and 178:
9 CONTENTS Polymeric Conjugates for
Page 179 and 180:
Polymeric Conjugates for Angiogenes
Page 181 and 182:
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
Page 189 and 190:
Page 191 and 192:
Page 193 and 194:
Page 195 and 196:
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
10 CONTENTS Poly(L-Glutamic Acid):
Page 205 and 206:
Poly(L-Glutamic Acid): Efficient Ca
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217:
Page 220 and 221:
202 development. For example, styre
Page 222 and 223:
204 blood circulation time and pref
Page 224 and 225:
206 11.3.2 MR IMAGING OF A PARAMAGN
Page 226 and 227:
208 FIGURE 11.6 Coronal MR slice im
Page 228 and 229:
210 strong enhancement in the heart
Page 230 and 231:
Page 232 and 233:
216 Research in the past decade has
Page 234 and 235:
218 While the majority of work on t
Page 236 and 237:
220 12.4.2.1 Integrins as Targets f
Page 238 and 239:
222 cytotoxicity. Consequently, enc
Page 240 and 241:
224 are lectin-carbohydrate, ligand
Page 242 and 243:
226 H1299 cells was significantly i
Page 244 and 245:
Page 247 and 248:
13 CONTENTS Long-Circulating Polyme
Page 249 and 250:
Long-Circulating Polymeric Nanopart
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
Page 259 and 260:
14 CONTENTS Biodegradable PLGA/PLA
Page 261 and 262:
Biodegradable PLGA/PLA Nanoparticle
Page 263 and 264:
Page 265 and 266:
Page 267 and 268:
15 CONTENTS Poly(Alkyl Cyanoacrylat
Page 269 and 270:
Poly(Alkyl Cyanoacrylate) Nanoparti
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
16 CONTENTS Aptamers and Cancer Nan
Page 307 and 308:
Aptamers and Cancer Nanotechnology
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Page 329:
Page 332 and 333:
318 17.5.3.2 Paclitaxel Formulation
Page 334 and 335:
320 TABLE 17.1 Examples of Polymers
Page 336 and 337:
322 are block copolymer vesicles th
Page 338 and 339:
324 17.2.4 PROPERTIES OF MICELLE FO
Page 340 and 341:
Page 342 and 343:
328 The amphiphilic or polar nature
Page 344 and 345:
330 of paclitaxel-loaded micelles.
Page 346 and 347:
332 of intracellular drug accumulat
Page 348 and 349:
334 organelles, the non-ionic Pluro
Page 350 and 351:
Page 352 and 353:
338 foreign bodies present within t
Page 354 and 355:
340 PEG-b-PDLLA copolymers. Therefo
Page 356 and 357:
342 For in vivo delivery, the LCST
Page 358 and 359:
344 In cases where nuclear targetin
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 371 and 372:
18 PEO-Modified Poly(L-Amino Acid)
Page 373 and 374:
PEO-Modified Poly(L-Amino Acid) Mic
Page 375 and 376:
Page 377 and 378:
Page 379 and 380:
Page 381 and 382:
Page 383 and 384:
Page 385 and 386:
Page 387 and 388:
Page 389 and 390:
Page 391 and 392:
Page 393 and 394:
Page 395 and 396:
Page 397:
Page 400 and 401:
Page 402 and 403:
388 Hydrophilic block Single polyme
Page 404 and 405:
390 concentrations, and organic sol
Page 406 and 407:
392 micelles used for solubilizatio
Page 408 and 409:
394 N O NH2 Nicotinamide Sodium nic
Page 410 and 411:
396 hydrotropic moieties. The main
Page 412 and 413:
TABLE 19.4 Modified Hydrotropic Mon
Page 414 and 415:
Page 416 and 417:
402 The loading content of paclitax
Page 418 and 419:
404 concentrations that are clinica
Page 420 and 421:
Page 422 and 423:
Page 424 and 425:
410 bioavailability, certain clinic
Page 426 and 427:
412 It has been shown that the EPR
Page 428 and 429:
O 2 N O C O O 2 N O C O O O C NO 2
Page 430 and 431:
416 and eventually drug could be cl
Page 432 and 433:
Page 434 and 435:
Page 436 and 437:
422 the process of chemotherapy. De
Page 438 and 439:
Page 440 and 441:
426 were measured. Cell incubation
Page 442 and 443:
428 drug-loaded nanoparticles. It w
Page 444 and 445:
430 DOX Concentration in plasma, μ
Page 446 and 447:
432 Counts 10 0 150 120 90 60 30 0
Page 448 and 449:
434 Tumor volume, mm 3 2500 2000 15
Page 450 and 451:
436 dramatically increased intracel
Page 452 and 453:
438 21.6 CONCLUSIONS In animal mode
Page 454 and 455:
Page 457 and 458:
22 CONTENTS Polymeric Micelles Targ
Page 459 and 460:
Polymeric Micelles Targeting Tumor
Page 461 and 462:
Page 463 and 464:
Page 465 and 466:
Page 467 and 468:
Page 469 and 470:
Page 471 and 472:
Page 473 and 474:
Page 475 and 476:
Page 477 and 478:
Page 479 and 480:
23 CONTENTS cRGD-Encoded, MRI-Visib
Page 481 and 482:
MRI-Visible Polymeric Micelles 467
Page 483 and 484:
Page 485 and 486:
Page 487 and 488:
Page 489:
Page 492 and 493:
478 A series of recent developments
Page 494 and 495:
480 O HN O O O O N O H H O H H OH O
Page 496 and 497:
482 Tumor volume (mm 3 ) 2000 1500
Page 498 and 499:
484 24.4 CONCLUSIONS Polymeric gene
Page 500 and 501:
Page 502 and 503:
490 25.2 DRUG DELIVERY 25.2.1 INTRO
Page 504 and 505:
Page 506 and 507:
494 intracellular DOX concentration
Page 508 and 509:
496 H 2 N H 2 N N H O H N 2 N H NH
Page 510 and 511:
498 incorporated in the PIC micelle
Page 512 and 513:
Page 514 and 515:
502 control polymer, Exgen 500. Thi
Page 516 and 517:
504 photocytotoxicity in HeLa cells
Page 518 and 519:
Page 520 and 521:
Page 522 and 523:
510 H 2N H 2N H N O H N Intermediat
Page 524 and 525:
512 O 2N O HN O O O O OR O HN O O O
Page 526 and 527:
514 making them useful in biologica
Page 528 and 529:
516 x x x x x x x x O O O O O O x O
Page 530 and 531:
518 tumors with little concentratio
Page 532 and 533:
Page 535 and 536:
27 CONTENTS PEGylated Dendritic Nan
Page 537 and 538:
PEGylated Dendritic Nanoparticulate
Page 539 and 540:
Page 541 and 542:
Page 543 and 544:
Page 545 and 546:
Page 547 and 548:
Page 549 and 550:
Page 551 and 552:
Page 553 and 554:
Page 555 and 556:
Page 557 and 558:
Page 559 and 560:
Page 561:
Page 564 and 565:
552 28.2.2.1 Long-Term Toxicity Stu
Page 566 and 567:
Page 568 and 569:
Page 570 and 571:
558 considerably simplified using h
Page 572 and 573:
Page 574 and 575:
562 FIGURE 28.8 PAGE electropherogr
Page 576 and 577:
564 28.1.5.4 Synthesis of Tritium L
Page 578 and 579:
566 10 nm Nanotechnology for Cancer
Page 580 and 581:
568 Rel % 60 50 40 30 20 10 LBCB-6-
Page 582 and 583:
570 25 nm (a) (b) 20.51 nm 27.82 nm
Page 584 and 585:
572 architecture (fenestrated struc
Page 586 and 587:
574 nanoparticle aggregates that sh
Page 588 and 589:
576 harvested, weighed, and process
Page 590 and 591:
578 Biodistribution of 5 nm Positiv
Page 592 and 593:
580 surface Au-composite nanodevice
Page 594 and 595:
582 28.2.2.2 Long-Term Toxicity of
Page 596 and 597:
584 Targeted RadioTherapy (StaRT) i
Page 598 and 599:
586 REFERENCES Nanotechnology for C
Page 600 and 601:
Page 602 and 603:
Page 604 and 605:
Page 606 and 607:
596 range (!200 nm size) and can be
Page 608 and 609:
Page 610 and 611:
Page 612 and 613:
Page 614 and 615:
Page 616 and 617:
Page 618 and 619:
Page 620 and 621:
Page 623 and 624:
30 CONTENTS Positively-Charged Lipo
Page 625 and 626:
Positively-Charged Liposomes for Ta
Page 627 and 628:
Page 629 and 630:
Page 631 and 632:
Page 633 and 634:
Page 635 and 636:
Page 637:
Page 640 and 641:
630 development because of poor pha
Page 642 and 643:
Page 644 and 645:
Page 646 and 647:
636 FIGURE 31.1 The enhancement of
Page 648 and 649:
Page 650 and 651:
Page 653 and 654:
32 CONTENTS RGD-Modified Liposomes
Page 655 and 656:
RGD-Modified Liposomes for Tumor Ta
Page 657 and 658:
Page 659 and 660:
Page 661 and 662:
Page 663 and 664:
Page 665 and 666:
Page 667 and 668:
Page 669 and 670:
Page 671:
Page 674 and 675:
664 of tissue specificity, and they
Page 676 and 677:
666 OH N H N 2N N N Folic acid NH
Page 678 and 679:
Page 680 and 681:
670 FIGURE 33.3 FR-mediated endocyt
Page 682 and 683:
672 FR-b expression seems to be a p
Page 684 and 685:
Page 687 and 688:
34 CONTENTS Nanoscale Drug Delivery
Page 689 and 690:
Nanoscale Drug Delivery Vehicles fo
Page 691 and 692:
Page 693 and 694:
Page 695 and 696:
Page 697 and 698:
Page 699 and 700:
Page 701 and 702:
Page 703 and 704:
Page 705 and 706:
Page 707 and 708:
Page 709 and 710:
Page 711 and 712:
Page 713 and 714:
Page 715 and 716:
Page 717 and 718:
Page 719 and 720:
Page 721 and 722:
Page 723 and 724:
Page 725 and 726:
Page 727 and 728:
Page 729:
Page 732 and 733:
724 The term macroemulsion is somet
Page 734 and 735:
726 W Oil Water-in oil (W/O emulsio
Page 736 and 737:
728 light scattering), counting (e.
Page 738 and 739:
730 rhizoxin. 31,35 When lecithin w
Page 740 and 741:
732 TABLE 35.3 Area Under the Perce
Page 742 and 743:
734 cholesterol oleate as lipids, e
Page 744 and 745:
736 REFERENCES Nanotechnology for C
Page 746 and 747:
Page 749 and 750:
36 CONTENTS Solid Lipid Nanoparticl
Page 751 and 752:
Solid Lipid Nanoparticles for Anti-
Page 753 and 754:
Page 755 and 756:
Page 757 and 758:
Page 759 and 760:
Page 761 and 762:
Page 763 and 764:
Page 765 and 766:
Page 767 and 768:
Page 769 and 770:
Page 771 and 772:
Page 773 and 774:
Page 775 and 776:
Page 777 and 778:
Page 779 and 780:
Page 781 and 782:
Page 783 and 784:
Page 785 and 786:
37 CONTENTS Lipoprotein Nanoparticl
Page 787 and 788:
Lipoprotein Nanoparticles as Delive
Page 789 and 790:
Page 791 and 792:
Page 793:
Page 796 and 797:
788 i.e., the molecular targets of
Page 798 and 799:
790 by apoptosis-triggering drugs.
Page 800 and 801:
Page 802 and 803:
794 Paclitaxel / DQA (molar) 0.9 0.
Page 804 and 805:
796 Considering that paclitaxel, ge
Page 806 and 807:
Page 808 and 809:
Page 810 and 811:
Page 813:
Section 2 Polymer Conjugates q 2006
Page 817:
Section 4 Polymeric Micelles q 2006
Page 821:
Section 6 Liposomes q 2006 by Taylo
show all

q 2006 by Taylor & Francis Group, LLC - Developers

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?